Create Free Account

By creating account you will get access to hot stocks & personalised emails

Avecho Biotechnology Ltd

Healthcare AU AVE

0.004AUD
-(-%)

Last update at 2024-05-08T02:17:00Z

Day Range

0.0030.004
LowHigh

52 Week Range

0.0030.009
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -2.34239M -3.41612M -2.63485M 0.85M -3.99102M
Minority interest - - - - -
Net income -2.34874M -4.57013M -3.41846M 0.38M -3.99102M
Selling general administrative 2.26M 2.60M 1.79M 1.29M 2.75M
Selling and marketing expenses - - - - -
Gross profit 0.87M 0.51M 0.24M 4.02M 0.70M
Reconciled depreciation 0.23M 0.67M 0.54M 0.68M 0.73M
Ebit -2.56639M -3.40614M -2.62854M 0.97M -3.99102M
Ebitda -2.33604M -2.97755M -2.09191M 1.65M -3.26538M
Depreciation and amortization 0.23M 0.43M 0.54M 0.68M 0.73M
Non operating income net other - - - - -
Operating income -2.56639M -3.40614M -2.62854M 0.97M -5.32540M
Other operating expenses 4.19M 5.34M 3.79M 3.74M 6.58M
Interest expense 0.00635M 0.00997M 0.00592M 0.01M 0.09M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.00435M 0.00083M 0.00079M 0.00837M 0.04M
Net interest income -0.00200M -0.01480M -0.00513M -0.00266M 0.04M
Extraordinary items - - - - 0.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00635M 1.15M 0.78M 0.47M -
Total revenue 1.21M 0.79M 0.38M 4.24M 1.25M
Total operating expenses 3.93M 5.06M 3.65M 3.52M 6.02M
Cost of revenue 0.34M 0.29M 0.14M 0.21M 0.55M
Total other income expense net 0.22M -0.00997M -0.00631M -0.11965M 1.33M
Discontinued operations - - - - -
Net income from continuing ops -2.34239M -5.15367M -2.63485M 0.85M -3.99102M
Net income applicable to common shares -2.34239M -3.41612M -2.63485M 0.85M -3.99102M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 7.32M 3.35M 5.25M 3.35M 5.32M
Intangible assets - 0.03M 0.10M 0.43M 0.86M
Earning assets - - - - -
Other current assets 0.30M 0.24M 0.22M 0.24M 0.16M
Total liab 0.94M 0.92M 0.71M 0.70M 0.56M
Total stockholder equity 6.38M 2.42M 4.54M 2.65M 4.76M
Deferred long term liab - - - - -
Other current liab 0.51M 0.48M 0.54M 0.42M 0.36M
Common stock 244.61M 237.53M 237.60M 232.78M 232.63M
Capital stock - 237.53M 237.60M 232.78M 232.63M
Retained earnings -239.62752M -264.10433M -262.06726M -258.66115M -256.02629M
Other liab - - - 0.00339M 0.00360M
Good will - - - - -
Other assets 0.00000M - - - -
Cash 5.50M 1.47M 3.26M 1.87M 3.21M
Cash and equivalents - 1.47M 3.26M 1.87M 3.21M
Total current liabilities 0.84M 0.75M 0.70M 0.60M 0.54M
Current deferred revenue 0.16M - - - -
Net debt -5.32925M -1.22213M -3.17085M -1.70654M -3.11335M
Short term debt 0.08M 0.07M 0.08M 0.07M 0.09M
Short long term debt - - - - -
Short long term debt total 0.18M 0.25M 0.09M 0.17M 0.10M
Other stockholder equity - 0.02M 29.00M 28.54M 28.15M
Property plant equipment - 0.47M 0.34M 0.23M 0.18M
Total current assets 7.00M 2.85M 4.81M 2.69M 4.28M
Long term investments - - - - -
Net tangible assets - 2.40M 4.43M 2.22M 3.90M
Short term investments - 0.09M - - -
Net receivables 1.10M 0.75M 1.13M 0.48M 0.76M
Long term debt - - - - -
Inventory 0.10M 0.40M 0.20M 0.10M 0.15M
Accounts payable 0.09M 0.19M 0.08M 0.11M 0.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.40M 29.00M 29.00M 28.54M 28.15M
Additional paid in capital - - - - -
Common stock total equity - - - 232.78M 232.63M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.00000M - - - 1.04M
Deferred long term asset charges - - - - -
Non current assets total 0.32M 0.49M 0.44M 0.66M 1.04M
Capital lease obligations - 0.25M 0.09M 0.17M 0.10M
Long term debt total - 0.18M 0.01M 0.09M 0.00770M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.05312M -0.25873M -0.00436M 0.01M 0.04M
Change to liabilities 0.03M 0.03M 0.05M -0.39038M -0.78634M
Total cashflows from investing activities -0.05312M -0.20229M -0.00436M 0.01M 0.04M
Net borrowings -0.08021M -0.07232M -0.08250M -0.08944M -0.08944M
Total cash from financing activities -0.07822M 4.69M -0.08250M -0.08944M 1.36M
Change to operating activities 0.04M 0.04M -0.05342M 0.03M -0.22459M
Net income -2.34874M -5.15367M -2.63485M 0.85M -3.99102M
Change in cash -1.79655M 1.39M -1.33776M 1.10M -0.78743M
Begin period cash flow 3.26M 1.87M 3.21M 2.11M 2.90M
End period cash flow 1.47M 3.26M 1.87M 3.21M 2.11M
Total cash from operating activities -2.27299M 0.43M -1.42396M 1.18M -2.18747M
Issuance of capital stock 0.00199M 5.06M - - 1.37M
Depreciation 0.08M 0.43M 0.54M 0.68M 0.73M
Other cashflows from investing activities - 0.00053M 0.00079M 0.01M 0.04M
Dividends paid - - - - -
Change to inventory -0.20525M -0.09673M 0.05M -0.04891M 0.19M
Change to account receivables 0.40M -0.67165M 0.28M -0.07840M 1.72M
Sale purchase of stock 0.00199M -0.29420M - 0.00000M -0.01349M
Other cashflows from financing activities -0.08021M -0.07232M -0.08250M -0.08944M -2.18747M
Change to netincome 0.18M 0.58M 0.35M 0.13M 0.18M
Capital expenditures 0.05M 0.20M 0.00515M 0.00515M 0.00042M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.04M 0.52M 0.78M 0.09M 2.66M
Stock based compensation - - - - -
Other non cash items 2.27M 4.73M 2.10M -1.53341M 3.27M
Free cash flow -2.32611M -0.20282M -1.42911M 1.18M -2.18790M

Fundamentals

  • Previous Close 0.004
  • Market Cap12.68M
  • Volume512286
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.24251M
  • Revenue TTM0.47M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.79M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVE
Avecho Biotechnology Ltd		 - -% 0.004 - - 33.46 2.48 22.21 -3.2435
CSL
CSL Ltd		 -0.13 0.05% 279.43 35.44 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.17 1.14% 15.14 748.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 -0.33 1.63% 19.92 15.98 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 -0.055 4.68% 1.12 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Avecho Biotechnology Limited, a biotechnology company, engages in the development and commercialization of human and animal health related products using its proprietary drug delivery system and Tocopherol Phosphate Mixture in Australia. The company operates through Production and Human Health segments. It also produces and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. In addition, the company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. Further, it develops feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney for treatment of osteoarthritis. The company was incorporated in 1992 and is based in Clayton, Australia.

Avecho Biotechnology Ltd

2A Westall Road, Clayton, VIC, Australia, 3168

Key Executives

Name Title Year Born
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Exec. Officer NA
Dr. Roksan Libinaki Ph.D. Chief Operating Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A., CA Company Sec. & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA
Ms. Melanie Jaye Leydin B.Bus, C.A. Company Secretary & CFO 1973
Dr. Paul Gavin BSc (Hons), Ph.D. Chief Executive Officer NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.